Â鶹ÊÓƵ

Dr. Selvaskandan is an NIHR clinical lecturer of nephrology with an interest in glomerular diseases, medical technology and artificial intelligence in kidney disease. His research with the Mayer IgA nephropathy laboratories utilises methods including digital spatial profiling, laser capture micro-dissection, fluorescence-activated cell sorting and RNA-seq. Dr. Selvaskandan also has interests in applying artificial intelligence and machine learning methods to solve problems in clinical nephrology, and is developing skillsets in bioinformatics, python and R. Dr. Selvaskandan has secured over £700,000 in competitive funding for research, and has published widely in his fields of interest. 

Dr. Selvaskandan supports a variety of clinical trials for kidney disease with Leicester's Renal Clinical Research Team, was chair of the College of Life Science's Fellows Forum, is an executive committee member of the UK Kidney Association's Renal SpR Club, and is on the executive board of the UK Kidney MedTech Network.

Role of monocytes and glomerular endothelial cells in the formation of endocapillary hypercellularity in IgA Nephropathy.
Kidney Research UK, Kidney Care Appeal & NIHR Bioresource funded, Primary Investigator 

IgA nephropathy (IgAN) is the most common cause of primary kidney disease in the world. It affects young adults, 20-40% of whom progress to total kidney failure within 20-30 years of diagnosis. New treatments for the condition are needed, and studying a lesion in the kidney called endocapillary hypercellularity (E1) may provide an avenue for this. E1 consists of inflammatory cells (called macrophages, which are likely to develop from cells known as monocytes in the blood) within the blood vessels of the filtration system of the kidney (glomerular endothelial cells). E1 seems to be reversible with treatments that suppress the body's immune system. However, we know that suppressing the immune system to treat IgAN can carry serious risks. 

This funded project will delineate which genes are switched on and off in the monocytes and glomerular endothelial cells of those with IgAN who have E1 and those that don't. This will be achieved using techniques including digital spatial profiling, laser capture micro-dissection, fluorescence activated cell sorting and RNA sequencing. Differences between the two groups, and cell-cell interactions will be modelled and explored using bioinformatic tools built on R based platforms. Findings will be validated using dynamic in vitro models, to determine if any dysregulated pathways can be interrupted for therapeutic benefit. 

Developing and evaluating an artificial intelligence powered tool to support patients with IgA Nephropathy.
Kidney Research UK funded, Primary Investigator 

Being slowly progressive IgA Nephropathy is managed through out- patient clinic visits; diagnosis and management plans are discussed in 10-15 minute appointments that occur 2 – 4 times a year. Patients are inevitably left with questions between consultations, but reliable sources of information can be challenging to identify; a google search for “IgA nephropathy” yields over 290,000,000 results. A successful alternative to this has been patient support groups, where patients support each other with personal experience and knowledge. However, specialist knowledge may not be available, the forums may not be accessible due to language barriers, and some feel uncomfortable discussing their health in relatively open communities. This project is looking to develop and evaluate an artificial intelligence powered tool to support patients with a diagnosis of IgA Nephropathy.

Evaluating the role of lectin pathway activation in flares of IgA Nephropathy
Industry Funded  (Omeros), Primary Investigator 

Pain over the kidneys can be a common symptom in IgA nephropathy, but very little is understood about it. A study performed in Leicester, funded by Kidney Research UK, examined over 20,000 postings on social media and confirmed pain as a symptom widely experienced by those with IgAN. The incidence of IgAN peaks among young adults, and it is therefore likely this symptom confers significant psychosocial and socioeconomic impacts at both an individual and a societal level.

Artificial Intelligence and Acute Kidney Injury
NHS Digital Funded, Primary Investigator 

Acute kidney injury (AKI) refers to an abrupt disruption of kidney function, and complicates 13-18% of all hospital admissions in the UK. The cost associated with managing AKI is accordingly significant, estimated as being between £434 and £620 million every year. AKI can occur for many reasons including dehydration, low blood pressure, infections, and commencing medications that maybe toxic to the kidneys. For this reason, most AKIs in hospital occur in settings outside of specialist kidney units, and may not always be managed appropriately. In keeping with this, the mortality associated with AKIs are exceptionally high at 25-30%.  
 
This project will explore if artificial intelligence can be used to predict which patients will develop the most severe forms of AKI.

Book Chapters:

1. IgA Nephropathy

   Selvaskandan H and Barratt J. GlomPedia (July 2024)

    

2. Chronic Kidney Disease, Proteinuria & Haematuria

            Selvaskandan H, Hull K, Barratt J. Best of Five MCQs for the ESE(Neph), Oxford University Press (2024)

    

3. IgA Nephropathy & Henöch-Schonlein purpura.

            Selvaskandan H, Cheung CK, Barratt J. Primer on Nephrology, Springer (2022)

    

   Reviews

   
   

    

    

4. IgA Nephropathy: a paradigm shift in treatment strategies

   Roberts L, Jones M, Barratt J, Selvaskandan H.Curr Opin Nephrol. Sep 2025; 1;34(5):381-388

    

5. IgA Nephropathy: an overview of active clinical trails

   Ghozloujeh Z, Selvaskandan H, Wiegley N et al. Kidney Med.  Aug 2025; 7(10):101708

    

6. The pathogenesis of IgA nephropathy and implications for treatment

   Cheung CK, Alexander S, Reich HN, Selvaskandan H et al. Nat Rev Neprhol. Jan 2025; (1)9-23

    

7. IgA Nephropathy: Emerging mechanisms of Disease

   Roberts L, Williams C, Barratt J Oni L, Selvaskandan HInd J Neph. 2024 July-Aug; (34(4):297-309

    

8. Primary IgA Nephropathy: new insights and emerging therapies  

   Selvaskandan H, Jhevari K, Rizk D. Adv Kidney Dis Health. 2024 May;31(3):180-193

    

9. A review of focal segmental glomerulosclerosis classification with a focus on genetic associations.

   Bonilla M, Efe O, Selvaskandan H, Lerma EV, Wiegley N Kidney Med. April 2024 6(6):100826

    

10. Technological Innovations to Improve Patient Engagement in Nephrology.

    Selvaskandan H, Gee PO, Seethapathy H. Adv Kidney Dis Health. 2024 Jan;31(1):28-36.

     

11. Novel Paradigms in Treatment: IgA Nephropathy 

    Selvaskandan H, Barratt J, Cheung CK. Kid Int Rep. 2023 Dec;9(2):203-213

     

12. IgA nephropathy: an overview of drug treatments in clinical trials.

    Selvaskandan H, Gonzalez-Martin G, Barratt J, Cheung CK. Expert Opin Investig Drugs. 2023 Jan 1:1-18.

     

13. Clinical application of microRNAs in glomerular diseases

    Selvaskandan H, Pawluczyk I, Barratt J. Nephrol Dial Transplant. 2022 July 30;gfac230

     

14. Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link

    Selvaskandan H, Cheung CK, Barratt J Journal of Immunogenetics.2022 Feb;49(1):8-21

     

15. New insights into the pathogenesis and treatment strategies in IgA nephropathy 

    Scionti K, Molyneux K, Selvaskandan H, Barratt J, Cheung CK Glomerular Diseases. 2022 Jan;2:15-29

     

16. Managing Crescentic IgA Nephropathy

    Selvaskandan H. ASN Kidney. 2021 Dec;13(12);20-21

     

17. The non-coding RNA landscape in IgA nephropathy – where are we in 2021?

    Pawluczyk I, Selvaskandan H, Barratt J. Journal of Clinical Medicine. 2021 May;27:13(5):e15270

     

18. Monitoring immune responses in IgA Nephropathy: biomarkers to guide management

    Selvaskandan H, Shi S, Twaij S, Cheung CK, Barratt J. Frontiers in Immunology. 2020 Oct;11:572754

     

19. New Strategies and Perspectives in Treating IgA Nephropathy 

             Selvaskandan H, Cheung CK, Muto M, Barratt J. Clin Exp Nephrol. 2019 May;23(5):577-588.

     

20. IgA Nephropathy: Driving innovation with a rare renal disease registry. 

             Selvaskandan H, Dillon M, Barratt J. Journal of Kidney Care. 2017 Jul; 2(4):205-211

     

21. MicroRNAs: A new avenue to understand, investigate and treat IgA Nephropathy?

             Selvaskandan H  and Pawluczyk I, Barratt J. Clinical Kidney Journal. 2018 Feb;11(1):29-37

     

    Original Research:

     

22. The Characterisation of Loin Pain in IgA Nephropathy

    Newman K, Barratt J, Szklarzewicz J, Roberts L, Thomas R, Mellon L, Smith A, Gale D, Wong K, RaDaR, Selvaskandan H,Kidney Int Rep. 2026 Accepted for publication

     

23. B cell derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy

    Pawluczyk IZA, Bachu JS, Brown JR, Lacey M, Mbadugha C, Straatman K, Wimbury D, Selvaskandan H, Barratt J. Kidney Int. 2025 Jul 108(1):119-135

     

24. Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients. 

    Wall N, Lamerton R, Ashfrod F, Perez-Toledo M, Jasiulewicz, Banham G, Newby M, Faustini S, Richter A, Selvaskandan H, et al. Vaccines. 2024 Dec; 13(1):7 

     

25. Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.

    Vaz de Castro PAS, Amaral AA, Almeida MG, Selvaskandan H, Barratt J, Simões E Silva AC.  J Nephrol. 2024 Mar 1. doi: 10.1007/s40620-023-01874-8. 

     

26. Risk Factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multi-centre cross-sectional study.

    Selvaskandan H, Hull KL, Adenwalla SF, Ahmed S, Cusu MC, Graham-Brown M, Gray L, Hall M, Hamer R, Kanbar A, Kanji H, Lambie M, Lee HS, Mahdi K, Major RW, Medcalf JF, Natarajan S, Oseya B, Stringer S, Tabinor M, Burton JO BMJ Open, 2022 May 30;12(5):e054869 

     

27. Regional variations in nephrology trainee confidence with clinical skills may relate to the availability of local training opportunities in the UK; results from a national survey

    Selvaskandan H, Baharani J, Hamer R. Clinical and Experimental Nephrology. 2022 May 7:1-12

     

28. Burnout and Long COVID among the UK nephrology workforce: results from a national survey investigating the impact of COVID-19 on working lives. 

    Selvaskandan H, Nimmo A, Savino M, Afuwape S, Brand S, Graham-Brown M, Medcalf J, Cockwell P, Beckwith H. Clinical Kidney Journal. 2022 Mar;15(3):517-526

     

29. A pilot study to predict risk of IgA nephropathy progression based on miR-204 expression. 

    Pawluczyk I, Nicholson M, Barbour S, Er L, Selvaskandan H, Bhachu JS, Barratt J. Kidney International Reports. 2021 Jun 5;6(8):2179-2188.

     

30. An ethnic variation in the acceptance of biologic disease modifying therapies: a university hospital experience.  

    Selvaskandan H, Moorthy A. Cureus.2021; May;13(5): e15270. doi:10.7759/cureus.15270

     

31. Seroprevalance of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving haemodialysis: a call to arms.

    Billany RE, Selvaskandan H, Adenwalla SF, Hull KL, March DS, Burton JO, Bishop NC, Carr EJ, Beale R, Tang JW, Bird PW, Holmes CW, Baines R, Brunskill NH, Graham-Brown MPM Kidney International.2021; Jun;99(6):1492-1494.

     

32. Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in IgA Nephropathy.

    Pawluczyk I, Soares M, Barratt W, Brown J, Bhachu J, Selvaskandan H, Zeng Y, Sarania R, Molyneux K, Roberts I, Barratt J. Nephrology Dialysis Transplantation. 2020 Nov;35(11):1865-1877

     

33. Acoustic Trauma slows AMPAR-mediated EPSCs in the auditory brainstem reducing GluA4 subunit expression as a mechanism to rescue binaural function. 

             Pilati N, Linley D, Selvaskandan H, Uchitel O, Hennig M, Kopp-Scheinpflug C, Ian D.                       Forsythe. Journal of Physiology. 2016 Jul; 594(13):3683-703. PMID: 27104476

     

    Case Reports:

     

34. Acute respiratory distress syndrome driven by severe hypercalcaemia and acute kidney injury: a case report and literature review of a rare, life threatening complication

    Selvaskandan H, Hull K, Gregory R, Pan D, Macriyiannis T, Briggs J, Richards C, Mason C, Jesus-Silva J, Bell R. Clin Nephrol Case Stud. 2022 Jan;10:21-27

     

35. Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis associated nephritis.

    Selvaskandan H, Cheung CK, Dormer J, Martinez M, Xu G, Barratt J. Nephron. 2020:144(9);453-458

     

36. Diabetic Myonecrosis in End Stage Renal Disease.

             Selvaskandan H, Amablawaner K, Westacott R. Clin Nephol Case Stud. 2019 Jul 12;7:41-45

     

37. High dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long standing infected ulcers

             Selvaskandan H, Denton-Beaumont R, Hamilton R. J Antimicrob chemother. 2019 Jun 1;74(6):                1755-1757.

     

38. Microangiopathic haemolytic anaemia in a young female. 

             Selvaskandan H, Karavadra M, Paramasperan K, Glasby M, Iyasere O. Kidney Int. 2019 May;95(5): 1277-1278.

     

    Editorials:

     

39. Should histology guide treatment decisions in IgA nephropathy?

    Selvaskandan H, Seethapathy H. Kidney International Reports Sep 2025;10(11):3270-3723.

     

40. The COVID-19 vaccination and IgA Nephropathy: Further cause for reassurance

    Selvaskandan H, Barratt. J Kidney International Sep 2024;5(9):1229-1231.

     

41. The microbiome and IgA nephropathy: a new avenue for treatment?

    Selvaskandan H, Barratt. J Kidney International Aug 2024;S0085-2538(24)00621-5.

     

42. Dynamic individualized risk prediction in IgA nephropathy: entering the era of artificial intelligence

    Selvaskandan H, Barratt. J Clin J Am Soc Nephrol July 2024; 19(7):826-828

     

43. Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?

    Selvaskandan H, Barratt. J Kidney International Apr 2024; 105(4):659-661

     

    Letters:

     

44. Impact of the COVID-19 pandemic on training, morale and well-being amongst the UK renal workforce.

    Beckwith H, Nimmo A, Savino M, Selvaskandan H, Graham-Brown MPM, Medcalf J, Cockwell P. Kidney International Reports.Mar 2021; 15;6(5):1433-1436.

     

45. The Exclusion of patients with chronic kidney disease in prospectively registered interventional trials for COVID-19. A Rapid review of international registry data,

    Major RW, Selvaskandan H, Makkeyah Y, Hull KL, Kurverji A, Graham-Brown MPM. Journal of the American Society of Nephrology. 2020. Sep:ASN.2020060877 (online ahead of print)

     

46. View from here: Prescribing Skills Assessment.

             Selvaskandan H, Baheerathan A. Clinical Teacher. 2014 Feb;11(1):58-9. PMID: 24470836

     

47. View from here: Smart Phones & Medical Education. 

             Baheerathan A, Selvaskandan H.Clinical Teacher. 2014 Oct;11(6):485-6. PMID: 25212943

     

48. The importance of counseling in young, female epileptic patients. 

             Baheerathan A, Selvaskandan H. J of Paediatr Neurosci. 2013 Sep;8(3):265. PMID: 24470836        

     

    Published abstracts:

     

49. Loin pain in rare kidney disease: analysis of 3867 questionnaire responses with linked data from the UK national registry of rare kidney diseases (RaDaR)

    Wong K, Newman K, Selvaskandan H, et al. KI Reports. 2025 Feb 10(2):S230-321. 

     

50. Exploring the impact of loin pain in IgA nephropathy: a UK wide mixed-methods qualitative study

    Newman K ,…., Selvaskandan H.JASN. 2024 

     

51. Towards an IgA nephropathy atlas

    Saez-Rodriguez J, Barratt J, Selvaskandan H, Duivenvoorden R, Kretzler M, Mariani L, Berthier C, Witsap A, Oloason H, Wenerson A, Gesualdo L, Nystrom J. KI Reports. 2024 Apr;9(Suppl4):177-178. 

     

52. #715 Loin pain in adults with IgA nephropathy: insights from qualitative interviews with patients, families, and healthcare professionals. 

    Newman K… Selvaskandan H. Nephrology Dialysis Transplantation, Volume 40, Issue Supplement_3, October 2025, gfaf116.0260

     

53. Toward Consensus on Glomerular Disease Centers of Excellence: Results from a Delphi Panel Study: SA-PO0794. 

    Norouzi S.. Selvaskandan H.. Poyan Mehr A. Journal of the American Society of Nephrology36(10S):10.1681/ASN.2025wtrh1cge, October 2025.

     

54. Can artificial intelligence predict the need for acute renal replacement therapy among inpatients with acute kidney injury?

    Selvaskandan H, Gaultney T, Heath D, Linfoot S, Xu G. Future Healthc J. 2023 Nov;10(Suppl 3):19-20. 

     

55. Digital spatial profiling can be used to study glomerular endothelial cells in IgA Nephropathy 

    Selvaskandan H, Boys, C, Pawluczyk I, Barratt J. Nephrol Dial Trans.2023 June;38(1)

     

56. WCN23-0066 Identifying druggable pathways in IgA nephropathy using spatial transcriptomics

    Selvaskandan H, Pawluczyk I, Barratt J. KI Reports.2023 Mar;8(3):S49-50

     

57. WCN23-0139 Leveraging modern machine learning tools to predict outcomes of in-patient acute kidney injury

    Selvaskandan H, Gauntley T, Heath D, Linfoot S, Xu G. KI Reports.2023 Mar;8(3):S98

     

58. Can artificial intelligence predict the need for acute renal replacement therapy among in-patients with acute kidney injury?

    Selvaskandan H, Gauntley T, Heath D, Linfoot S, Xu G. Future Healthcare J.2023 10.7861/fhj.10-2-S1

     

59. Macrophage derived products induce pro-inflammatory and pro fibrotic responses in renal collecting ducts: A potential role in the pathogenesis of IgA nephropathy?

    Pawluczyk I, Selvaskandan H, Zeng Y, Sarania R, Barratt J. Kidney Diseases. 2018 Sep;4(3):126

     

60. Is there an ethnic variation in the acceptance of biologic therapy among patients with axial spondyloathropathy? A university hospital experience. 

             Selvaskandan H, Moorthy A. Rheumatology. 2018 Apr; 57:key075.307

     

61. Ethnic Variation in the acceptance of biologic therapy among rheumatology patients - a university hospital experience. 

             Selvaskandan H, Al-Ani H, Moorthy A. Annals of the Rheumatic Diseases. 2017 Jun; 76:1436

     

     

    Affiliated publications:

     

     

62. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    RECOVERY Collaborative Group. Lancet Infect Dis.2026 Jan;(1):34-35

     

63. Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR registry. 

    RaDaR Consortium. Kidney Int.2025 Sep;108(3):455-469

     

64. Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

    RECOVERY Collaborative Group. Lancet.2025 September;doi: 10.1016/S1473-3099(25)00093-3

     

65. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

    RaDaR Consortium. Kidney Int Rep. 2024 May 9;9(7):2067-2083 epub ahead of print.

     

66. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results form a randomised, active controlled, phase 3 trial.

    PROTECT Investigators. Lancet. 2023 Nov epub ahead of print.

     

67. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

    RECOVERY Collaborative Group Lancet Diabetes Endocrinol. 2023 Dec  Epub ahead of print.

     

68. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

    RECOVERY Collaborative Group Lancet. 2023 Apr  Epub ahead of print.

     

69. Sparsentan in patients with IgA nephropathy; a pre-specified interim analysis from a randomised, double-blind, active-controlled clinical trial

    PROTECT Investigators. Lancet. 2023 Apr epub ahead of print.

     

70. RECOVERY Collaborative Group. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

    RECOVERY Collaborative Group. Lancet Child Adolesc Health. 2024 Mar;8(3):190-200. 

     

71. Immunomodulatory therapy in children with paediatric inflammatory multi-system syndrome temporally assosciated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): A randomised controlled open-label, platform trial. 

    RECOVERY Collaborative Group. Lancet Child Adolesc Health. 2024 Jan 15.

     

72. Cemdisiran Phase 2 Study Investigators and Collaborators. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.

    Cemdisiran Phase 2 Study Investigators and Collaborators. Clin J Am Soc Nephrol. 2024 Jan 15.

     

73. RECOVERY Collaborative Group. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

    RECOVERY Collaborative Group.. Lancet Child Adolesc Health. 2024 Mar;8(3):190-200. 

     

74. Effect of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.

    RaDaR consortium. Lancet. 2024 Mar epub ahead of print.

     

75. IgA nephropathy patient baseline characteristics in the Sparsentan PROTECT study. 

    PROTECT Investigators. KI Reports. 2023 Mar epub ahead of print.

     

76. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

    RECOVERY Collaborative Group. Lancet. 2022 Jul 30;400(10349):359-368

       

77. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.

    Haemodialysis COVID-19 consortium. Lancet. 2022 Feb 26; 399(10327):800-802

     

78. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): 

    RECOVERY Collaborative Group. Lancet. 2022 Feb 12;399(10325):665-676

     

79. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): 

    RECOVERY Collaborative Group. Lancet. 2022 Jan 8;399(10320):143-151

     

80. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. 

    Haemodialysis COVID-19 consortium. Lancet. 2021 Aug; S0140-6736(21)01854-7

     

81. Convalescent plasma in patients with in patients admitted to hospital with COVID-19 (RECOVERY): 

    RECOVERY Collaborative Group. Lancet. 2021 May;S0140-6736(21)00897-7

     

82. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)

    RECOVERY Collaborative Group. Lancet. 2021 May;397(10285):1637-1645

     

83. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY)

    RECOVERY Collaborative Group. Lancet. 2021 Feb 13;397(10274):605-612

     

84. Effect of Hydroxychloroquine in hospitalised patients with COVID-19 

    RECOVERY Collaborative Group. New England Journal of Medicine. 2020 Nov;383(21):2030-2040.

     

85. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY)

    RECOVERY Collaborative Group. Lancet.2020 Oct;396(10259): 

     

86. Dexamethasone in hospitalised patients with COVID-19: preliminary report

RECOVERY Collaborative Group. New England Journal of Medicine.2020 July;doi: 10.1056/NEJMoa2021436

Dr. Selvaskandan is currently supervising:

A post-doctoral researcher investigating the impact of loin pain in IgA Nephropathy 

A post-doctoral researcher investigating novel mechanisms of glomerular disease through the application of spatial transcriptomics 

A doctoral student investigating the impact of loin pain in IgA Nephropathy 

A doctoral student investigating novel mechanisms of glomerular disease through the application of spatial transcriptomics 

An academic foundation programme doctor applying spatial transcriptomics to paediatric glomerular diseases

An specialised foundation programme doctor applying digital spatial profiling methods to investigate the transcriptomic changes in kidney disease

An undergraduate student investigation interstitial responses in minimal change disease

Dr. Selvaskandan has previously supervised:

One masters student (graduated with distinction)

Current:

Renal Precision Medicine Module Tutor
Clinical Sciences Bachelor of Sciences Course

SSRR Module Tutor
Intercalated Masters of Science Course

GlomCon Workshop Faculty
The Glomerular Disease Study & Trial Consortium (GlomCon)

Nephrology Educational Seminars Co-ordinator, John Walls Renal Unit 
John Walls Renal Unit, University Hospitals of Leicester NHS Trust

Previous

Arterial Blood Gas Interpretation  
Developer of an interactive website ()

Acute Medical Care Simulation Facilitator 
University Hospitals of Leicester NHS Trust

Leicester Medical School Module Tutor
Leicester Medical School, Â鶹ÊÓƵ 

Leicester Medical School Examinations Standard Setting Committee  
Leicester Medical School, Â鶹ÊÓƵ

Chronic Kidney Disease - Mineral Bone Disease Management, Content Developer 
AMGEN sponsored educational seminar

East Midlands Core Medical Trainee Conference Organiser 
Health Education East Midlands

ELITE Medical Education Finals Course, Tutor  
ELITE medical education

Foundation Year Tutorial Scheme, Founder
Kettering General Hospital

Neurology Pre-clinical Teaching, Programme Lead 
Peer Led Teaching Initiative

2023 Kidney Research UK Driving Discoveries: Best Oral Presentation 
Kidney Research UK

2023 Cardiovascular Sciences Symposium: Best Poster
Â鶹ÊÓƵ

2023 Glomerular Diseases Theme: Best Poster
UK Kidney Week

2023 Doctoral College Symposium: Best Presentation 
Â鶹ÊÓƵ

2020 Endocrinology Society Prize
East Midlands Endocrinology Society

2017 David Ives Prize (1st Runner up)
University Hospitals of Leicester NHS Trust

2017 Midlands Rheumatology Society Presentation Prize (1st Runner up)
Midlands Rheumatology Society

2013 Frank Harris Prize
Leicester Medical School

2012 Peer Assisted Learning Award
Â鶹ÊÓƵ

In progress Masters of Science (Clinical Trials)

                                                University of Oxford

2024                      Doctor of Philosophy, PhD

                                                Â鶹ÊÓƵ

2020                                       European Speciality Exam in Nephrology, ESENeph

                                                ERA-EDTA, UK Renal Association, Royal College of Physicians (UK)

2019                                       Masters of Research Methods (Distinction), MRes

                                                Â鶹ÊÓƵ

2016                                       Membership to the Royal College of Physicians (UK), MRCP(UK)

                                                Royal College of Physicians

2013                                       Bachelor of Medicine, Bachelor of Surgery (Honours), MBChB(Hons)

                                                Â鶹ÊÓƵ

2011                                       Bachelor of Sciences (First Class, Honours), BSc(Hons)

                                                Â鶹ÊÓƵ

2015                                       Post-graduate Certificate in Medical Leadership (Distinction), PgCert

                                                Swansea University

2014                                       Post-graduate Certificate in Medical Education (Merit), PgCert

                                                Cardiff University